Annual report
8129.TEDINET S100OLHO
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥1.21T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥1.26T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.22T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.21T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥4.3bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.3bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.7bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.0bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.1bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥10.3bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.4bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥5.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥683.2bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥670.8bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥663.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥645.8bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥445.8bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥237.4bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥231.0bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥213.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥207.8bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥93.1bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥90.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥80.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.4bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥63.7bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥13.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥52.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥680m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥680m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥9.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥5.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.77 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥233.34 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.71 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.84 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.97 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥208.55 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥177.78 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥190.6 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥3,415.5 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,364.65 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,273.86 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,135.45 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,030.58 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 7,785 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 7,732 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 7,847 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 7,937 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 7,849 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥7.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥11.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥13.5bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥14.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥11.4bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥459m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥4.9bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.8bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.9bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥12.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥4.0bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥10.2bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.3bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥254.8bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥260.0bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥242.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥195.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥181.2bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥100.0bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥99.4bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥154.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥160.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥150.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥139.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥137.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥83.4bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥81.1bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥56.91 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.29 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.74 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.38 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.54 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥52.22 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥133.57 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥124.8 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.19 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.07 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,191.82 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,275.25 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,129.58 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,050.25 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,997.21 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.5% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 78,270,142 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 224 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 227 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 233 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 228 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 195 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥56.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥56.5bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥89.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Dispensing Pharmacyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥444m |
| Dispensing Pharmacyreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥902m |
| Dispensing Pharmacyreportable segment | employees | at 2022-03-31 | 2468 pure |
| Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥91.8bn |
| Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥91.8bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥14m |
| Dispensing Pharmacyreportable segment | segment assets | at 2022-03-31 | ¥54.2bn |
| Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥3.0bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥126m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥180m |
| Medical Products Manufacturing And Salesreportable segment | employees | at 2022-03-31 | 98 pure |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥9.1bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥7.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2022-03-31 | ¥17.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥884m |
| Medical Products Retailreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.7bn |
| Medical Products Retailreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.6bn |
| Medical Products Retailreportable segment | employees | at 2022-03-31 | 4800 pure |
| Medical Products Retailreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.22T |
| Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.17T |
| Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥47.9bn |
| Medical Products Retailreportable segment | segment assets | at 2022-03-31 | ¥535.2bn |
| Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥4.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.32T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.27T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥56.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥612.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | −¥28m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥52.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥52.2bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥111.2bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥2.4bn |
| Dispensing Pharmacyreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥1.9bn |
| Dispensing Pharmacyreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥802m |
| Dispensing Pharmacyreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥91.1bn |
| Dispensing Pharmacyreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥91.1bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥8m |
| Dispensing Pharmacyreportable segment | segment assets | at 2021-03-31 | ¥53.2bn |
| Dispensing Pharmacyreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.7bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥132m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥8m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥8.1bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥5.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2021-03-31 | ¥5.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥729m |
| Medical Products Retailreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥4.0bn |
| Medical Products Retailreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥3.6bn |
| Medical Products Retailreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥1.16T |
| Medical Products Retailreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥1.12T |
| Medical Products Retailreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥46.0bn |
| Medical Products Retailreportable segment | segment assets | at 2021-03-31 | ¥511.3bn |
| Medical Products Retailreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥6.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥4.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥1.26T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥1.21T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥52.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥572.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥6.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,101
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row26Member | Original text (Japanese)医薬品の仕入れ等の取引において緊密な関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row26Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row27Member | Original text (Japanese)住友ファーマ㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row27Member | Original text (Japanese)同上 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row27Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row28Member | Original text (Japanese)扶桑薬品工業㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row28Member | Original text (Japanese)同上 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row28Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row29Member | Original text (Japanese)東京海上ホールディングス㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row29Member | Original text (Japanese)取引関係強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row29Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row30Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row30Member | Original text (Japanese)医薬品の仕入れ等の取引において緊密な関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row30Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Original text (Japanese)㈱ほくやく・竹山ホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Original text (Japanese)同上 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)㈱みずほフィナンシャルグループ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)金融取引関係の維持のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)クリングルファーマ㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)医薬品の仕入れ等の取引において緊密な関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)㈱ヤクルト本社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)同上 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)㈱ビー・エム・エル | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)取引関係強化のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)シップヘルスケアホールディングス㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)取引関係強化のため株式分割のため株式数が増加 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)㈱スズケン | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)医薬品の仕入れ等の取引において緊密な関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row38Member | Original text (Japanese)科研製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row38Member | Original text (Japanese)同上 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row38Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row39Member | Original text (Japanese)㈱ジェイ・エム・エス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row39Member | Original text (Japanese)医薬品の仕入れ等の取引において緊密な関係を維持するため持株会による取得のため株式数が増加 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row39Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row40Member | Original text (Japanese)㈱三井住友フィナンシャルグループ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row40Member | Original text (Japanese)金融取引関係の維持のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row40Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row41Member | Original text (Japanese)日水製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row41Member | Original text (Japanese)医薬品の仕入れ等の取引において緊密な関係を維持するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row41Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row42Member | Original text (Japanese)日本ケミファ㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row42Member | Original text (Japanese)同上 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row42Member | Original text (Japanese)有 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |